Testing the Addition of an Individualized Vaccine to Nab-Paclitaxel, Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Anatomic Stage IV Breast Cancer AJCC v8|Invasive Breast Carcinoma|Metastatic Triple-Negative Breast Carcinoma
Interventions: PROCEDURE: Biopsy|PROCEDURE: Biospecimen Collection|DRUG: Carboplatin|PROCEDURE: Computed Tomography|BIOLOGICAL: Durvalumab|DRUG: Gemcitabine Hydrochloride|PROCEDURE: Magnetic Resonance Imaging|DRUG: Nab-paclitaxel|BIOLOGICAL: Personalized Synthetic Long Peptide Vaccine|DRUG: Poly ICLC|BIOLOGICAL: Tremelimumab
Sponsor: National Cancer Institute (NCI)